Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial

Sunvozertinib is an oral, irreversible, and selective tyrosine kinase inhibitor that has a favourable safety profile and encouraging antitumour activity, as shown in phase 1 studies of patients with heavily pretreated non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (exon20ins...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet respiratory medicine 2024-03, Vol.12 (3), p.217-224
Hauptverfasser:	Wang, Mengzhao, Fan, Yun, Sun, Meili, Wang, Yongsheng, Zhao, Yanqiu, Jin, Bo, Hu, Ying, Han, Zhigang, Song, Xia, Liu, Anwen, Tang, Kejing, Ding, Cuimin, Liang, Li, Wu, Lin, Gao, Junzhen, Wang, Jianghong, Cheng, Ying, Zhou, Jianying, He, Yong, Dong, Xiaorong, Yao, Yu, Yu, Yan, Wang, Huijie, Sun, Si, Huang, Jianan, Fang, Jian, Li, Wen, Wang, Lin, Ren, Xiubao, Zhou, Chengzhi, Hu, Yanping, Zhao, Dahai, Yang, Runxiang, Xu, Fei, Huang, Yijiang, Pan, Yueyin, Cui, Jiuwei, Xu, Yan, Yang, Zhenfan, Shi, Yuankai
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anemia Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics China ErbB Receptors - genetics Exons - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutagenesis, Insertional
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!